Ambien Cost in North Dakota 2026: Zolpidem Prices, Insurance, and Savings

What Generic Zolpidem Costs at North Dakota Pharmacies

The average cash price for a 30-day supply of generic zolpidem in North Dakota sits near $15 in 2026. That figure reflects immediate-release tablets at 5 mg or 10 mg, the most commonly prescribed strengths. Brand-name Ambien carries a manufacturer list price around $120 per month from Sanofi, but very few patients pay that amount since generics dominate the market.

Prices vary across pharmacies. A Walmart or Costco in Fargo or Bismarck may price a 30-count supply below $10, while an independent pharmacy in a smaller community might charge $18 to $25 without a discount card. The extended-release formulation (zolpidem ER, equivalent to Ambien CR) tends to cost more, often $25 to $45 for a generic 30-day fill, because fewer manufacturers produce it.

Zolpidem has been available as a generic since 2007, and price competition among manufacturers keeps costs low 1. The FDA approved the original Ambien (zolpidem tartrate) in 1992 for short-term treatment of insomnia, and the immediate-release generic market now includes more than a dozen approved ANDAs. For most North Dakota residents paying cash, zolpidem is one of the least expensive prescription sleep medications available.

Patients filling at chain pharmacies should compare prices directly. A simple phone call to two or three pharmacies, or a check through a discount pricing tool, can reveal a $5 to $15 spread on the same drug in the same city.

North Dakota Medicaid and Ambien Coverage

North Dakota Medicaid does not cover Ambien or generic zolpidem on its preferred drug list as of 2026. This exclusion applies to both the immediate-release and extended-release formulations.

Patients enrolled in North Dakota Medicaid who need pharmacotherapy for insomnia may find that their plan covers alternative agents. Trazodone (off-label for insomnia) and doxepin 3 mg or 6 mg (Silenor) are sometimes included on state Medicaid formularies at lower tiers. A prescriber can submit a prior authorization request for zolpidem if a clinical rationale exists, such as documented failure of covered alternatives or contraindications to them, but approval is not guaranteed.

The Endocrine Society and the American Academy of Family Physicians both note that cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment. North Dakota Medicaid does cover behavioral health services, so CBT-I may be accessible without the formulary restrictions that apply to sedative-hypnotics.

For patients whose prior authorization is denied, the cash price of $15 per month for generic zolpidem is often manageable out of pocket. Some community health centers in North Dakota participate in the 340B drug pricing program, which could reduce costs further for eligible patients 2.

Insurance Coverage Beyond Medicaid

Most commercial insurance plans in North Dakota place generic zolpidem on Tier 1 or Tier 2, meaning copays typically range from $0 to $15 per month. Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and Medica all offer plans sold on the state exchange, and generic sedative-hypnotics generally receive favorable formulary placement.

Brand-name Ambien, by contrast, may sit on a higher tier or require step therapy through the generic first. Because the generic is both cheaper and bioequivalent, insurers have little reason to cover the brand at a preferred level.

Medicare Part D plans in North Dakota also commonly cover generic zolpidem. During the initial coverage phase, a Part D enrollee might pay $1 to $10 for a 30-day supply depending on plan design. The 2026 Part D redesign, which caps annual out-of-pocket spending at $2,000, adds another layer of protection for patients who take multiple medications 3.

Patients should verify their specific formulary. A plan's drug list can change at the start of each calendar year, and mid-year formulary updates are possible for Medicare Advantage plans.

HealthRX Zolpidem Cost Decision Framework for North Dakota Residents:

| Situation | Recommended path | |---|---| | Have commercial insurance | Fill generic zolpidem at in-network pharmacy; expect $0 to $15 copay | | On Medicare Part D | Check formulary; generic usually Tier 1 at $1 to $10 | | On ND Medicaid | Not covered; ask prescriber about prior auth or alternatives | | Uninsured, cash pay | Use discount card at chain pharmacy; target $8 to $15 | | Need compounded formulation | Contact a licensed 503A pharmacy in ND |

Compounded Zolpidem in North Dakota

Compounded zolpidem is legal in North Dakota when prepared by a licensed 503A compounding pharmacy pursuant to a valid patient-specific prescription. A 503A pharmacy operates under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits compounding by a licensed pharmacist based on an individual prescription 4.

Why would a patient need compounded zolpidem? The most common reasons include allergy to an inactive ingredient in the commercial tablet, a need for a non-standard dose (such as 2.5 mg or 7.5 mg), or a requirement for a different delivery form like a sublingual troche or liquid suspension. Pediatric dosing, though rare for zolpidem, is another scenario.

North Dakota does not impose additional state-level restrictions on 503A compounding beyond federal requirements. The North Dakota Board of Pharmacy oversees compounding pharmacies operating within the state. Patients seeking compounded zolpidem should confirm that the pharmacy holds a current state license and follows USP 795 standards for non-sterile compounding.

Pricing for compounded zolpidem varies. Some 503A pharmacies price a 30-day supply competitively with the generic retail product, while others charge a compounding fee that pushes the cost to $30 to $60. Insurance plans rarely cover compounded medications, so most patients pay cash.

Telehealth Prescribing of Zolpidem in North Dakota

North Dakota permits telehealth prescribing of zolpidem. The state's telehealth parity law, updated in recent legislative sessions, allows providers licensed in North Dakota to prescribe controlled substances via audio-video visits when a legitimate provider-patient relationship has been established.

Zolpidem is a Schedule IV controlled substance under the DEA's classification. Federal regulations under the Ryan Haight Act historically required an in-person evaluation before prescribing controlled substances via telehealth, but the DEA's 2024-2025 rulemaking extended telehealth prescribing flexibilities 5. North Dakota's alignment with these federal updates means patients can obtain a zolpidem prescription through a telehealth platform without a prior in-person visit, provided the prescriber conducts an appropriate clinical evaluation.

This matters for North Dakota specifically. The state is geographically large with a population of roughly 780,000 spread across 70,000 square miles. Many residents live 60 or more miles from the nearest sleep specialist. Telehealth removes that barrier.

Patients using telehealth for zolpidem should expect a clinical assessment that includes sleep history, screening for obstructive sleep apnea (which requires different treatment), medication review for interactions, and discussion of non-pharmacologic strategies. A responsible prescriber will not simply write the prescription on request. The Krystal et al. (2010) polysomnographic study demonstrated that zolpidem 10 mg reduced wake time after sleep onset and increased total sleep time in adults with chronic insomnia, but the study also underscored the importance of proper patient selection 6.

How to Get the Lowest Price in North Dakota

Several strategies can push the cost of generic zolpidem below the $15 average.

Discount cards and coupons. GoodRx, RxSaver, and similar platforms aggregate discount pricing from pharmacy benefit managers. These tools frequently show zolpidem 10 mg #30 for $4 to $8 at North Dakota chains including Walmart, Walgreens, and CVS. The discount is applied at the point of sale and does not require insurance.

Manufacturer savings programs. Sanofi, which markets brand-name Ambien, has periodically offered savings cards, but these apply to the brand product and are less useful when generic zolpidem is already $15 or less. Generic manufacturers do not typically offer direct-to-patient discount programs. Patients asking about "the Sanofi savings card" should understand it reduces the brand copay, not the generic price. If a patient's insurance covers only brand Ambien at a high copay, the card might save $20 to $50 per fill, but switching to generic is almost always cheaper.

90-day fills. Some pharmacies and mail-order services price a 90-day supply at 2 to 2.5 times the 30-day price rather than 3 times. A patient paying $15 per month might get a 90-day supply for $30 to $38.

340B pharmacies. Federally qualified health centers and certain hospital outpatient pharmacies in North Dakota participate in the 340B program. Eligible patients can access medications at significantly reduced cost. Not all 340B sites pass savings to uninsured patients, so it is worth asking directly.

Pill splitting. Zolpidem 10 mg tablets are scored. A patient prescribed 5 mg can purchase 10 mg tablets and split them, effectively halving the per-dose cost. This should only be done with prescriber approval and is not appropriate for extended-release formulations, which must not be cut or crushed 7.

Safety Considerations for Zolpidem Use

Cost savings mean nothing if the medication is used unsafely. Zolpidem carries specific risks that North Dakota patients and prescribers should account for.

The FDA issued a 2013 safety communication lowering the recommended starting dose for women to 5 mg for immediate-release and 6.25 mg for extended-release, based on pharmacokinetic data showing that women clear zolpidem more slowly than men, leading to higher next-morning blood levels and impaired driving 7. This dose adjustment remains in effect.

Complex sleep behaviors, including sleepwalking, sleep-driving, and preparing food while not fully awake, have been reported. The FDA added a boxed warning in 2019 after reports of serious injuries and deaths associated with these behaviors 8.

"Patients with a history of complex sleep behaviors with any sedative-hypnotic should not be prescribed zolpidem," the FDA stated in its 2019 safety announcement 8.

Concurrent use of opioids, benzodiazepines, or alcohol increases the risk of respiratory depression. The American Academy of Sleep Medicine's 2017 clinical practice guideline for pharmacologic treatment of chronic insomnia recommended that clinicians use zolpidem, among other agents, only after considering CBT-I and weighing benefits against risks for each patient 9.

Dr. Andrew Krystal and colleagues noted in their 2010 Sleep study that "zolpidem significantly improved polysomnographic measures of sleep maintenance," but emphasized that treatment duration and patient monitoring remain important clinical considerations 6.

Alternatives to Zolpidem Available in North Dakota

Patients for whom zolpidem is too expensive, not covered, or clinically inappropriate have several options.

Trazodone (off-label, 25 to 100 mg at bedtime) costs $4 to $10 per month and is widely covered by Medicaid and commercial plans. It is not a controlled substance.

Doxepin (Silenor, 3 mg or 6 mg) is FDA-approved for insomnia characterized by difficulty with sleep maintenance. Generic doxepin at low doses costs $10 to $20 per month 10.

Suvorexant (Belsomra) and lemborexant (Dayvigo) are dual orexin receptor antagonists with different mechanisms than zolpidem. They are more expensive ($300+ per month at brand pricing) but may be covered at lower copays by some commercial plans.

Melatonin receptor agonists like ramelteon (Rozerem) target the circadian system rather than GABA-A receptors. Generic ramelteon costs $15 to $30 per month and is not a controlled substance.

CBT-I remains the gold standard. A 2016 meta-analysis published in Annals of Internal Medicine found that CBT-I produced clinically meaningful improvements in sleep onset latency and wake after sleep onset that persisted after treatment ended, unlike pharmacotherapy benefits, which typically stop when the medication is discontinued 11.